Sequana Medical 获得高达 6400 万欧元的资金，为其在美国推出经 FDA 批准的 alfapump® 提供资金。 Sequana Medical secures up to EUR 64 million, funding its FDA-approved alfapump® launch in the US.

Sequana Medical公司是一家研制各种疾病液体过重症治疗的公司,已经从主要股东那里获得400万欧元的资金,并且可能从GEM Global Yield LLC SCS公司获得6 000万欧元的资金。 Sequana Medical, a company developing treatments for fluid overload in various diseases, has secured EUR 4.0 million in financing from its major shareholders and a potential EUR 60 million from GEM Global Yield LLC SCS. 这笔资金将把该公司的金融跑道延长到2025年底,配合美国计划于2024年12月获得林业发展局批准的Alfapumpé装置的发射计划。 This funding will extend the company's financial runway to the end of 2025, aligning with the planned US launch of its alfapump® device, which received FDA approval in December 2024. alfapump® 旨在通过几乎消除对治疗性穿刺术的需求来改善患者的生活质量。 The alfapump® aims to improve patient quality of life by nearly eliminating the need for therapeutic paracentesis.